A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular Lymphoma

NCT04707079 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Follicular Lymphoma

Interventions

DRUG: Duvelisib

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.